Hemato Oncology Testing Market is set to reach USD 620 million by 2030, North America leads the market with 41.32% of market share | Major Players:- F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V.

The Global Hemato Oncology Testing Market reached USD 280 million in 2022 and is projected to witness lucrative growth by reaching up to USD 620 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030).

DataM Intelligence unveils its latest report on the "Hemato Oncology Testing Market size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/hemato-oncology-testing-market?pratik

United States: Key Industry Developments (2025)

✅ August 2025: Becton Dickinson launched next‐generation molecular testing kits for hematologic malignancies, enabling faster genetic profiling to support personalized treatment plans and improved diagnostic turnaround times.

✅ July 2025: Invitae expanded its hemato‐oncology testing services with an AI‐assisted genomic analysis platform, integrating clinical data to enhance targeted therapy decisions and clinical confidence in treatment recommendations.

✅ June 2025: Guardant Health introduced new liquid biopsy solutions for hematologic cancer monitoring, offering non‐invasive tracking of minimal residual disease and earlier intervention insights for clinicians.

Japan: Key Industry Developments (2025)

✅ September 2025: Sysmex Corporation launched an integrated hemato‐oncology testing platform that combines flow cytometry with genetic analysis to boost automation, precision, and workflow efficiency in Japanese diagnostic centers.

✅ July 2025: Sysmex expanded advanced hemato‐oncology testing platforms tailored for Japanese hospitals and diagnostics labs, focusing on precision, automation, and throughput improvements.

✅ June 2025: Fujirebio expanded biomarker‐based testing solutions for leukemia, lymphoma, and multiple myeloma, enhancing blood cancer detection and monitoring capabilities in clinical settings.

✅ May 2025: Takara Bio Inc. partnered with Japanese academic institutions to deploy next‐generation sequencing and cytogenetic testing for comprehensive hematologic cancer profiling.

✅ March 2025: Otsuka Pharmaceutical launched "Hemsight®" hematologic oncology gene panel test, now covered by insurance in Japan, enabling comprehensive genomic profiling to support diagnosis, prognosis, and treatment selection.

📌 Hemato Oncology Testing Market 2025-26 M&A Deals

→ In December 2025, Natera, Inc. acquired Foresight Diagnostics in an all‐stock transaction valued at $450 million-consisting of a $275 million upfront payment and up to $175 million in earn‐outs tied to milestones. The acquisition expands Natera's cancer minimal residual disease (MRD) and precision oncology testing capabilities.

→ In August 2025, Sonic Healthcare USA, Inc. acquired Cairo Diagnostics LLC, a provider of comprehensive hematology oncology diagnostics, to expand Sonic's national hematology and oncology testing footprint. Financial terms were not publicly disclosed.

→ In June 2025, QIAGEN N.V. entered a strategic collaboration with Incyte to co‐develop a next‐generation sequencing (NGS)‐based companion diagnostic panel for hematological malignancies, strengthening the onco‐hematology testing pipeline. This was a partnership, not a full acquisition.

→ In January 2025, Renovaro Inc. agreed to acquire Predictive Oncology in an all‐stock transaction to combine AI‐driven cancer diagnostics, biobank resources and multi‐omic drug response data platforms. Deal value was not disclosed publicly.

Market Growth Drivers:-

• Rising cancer incidence increases demand for precise diagnostics that enable early detection and ongoing monitoring - especially critical in life‐threatening blood cancers where timing influences survival.

• One research estimate notes that 63% of testing demand ties directly to growth in leukemia and lymphoma patient volumes.

• With a growing geriatric population more susceptible to hematologic malignancies, sustained increases in testing requirements are expected.

• Next‐Generation Sequencing (NGS), digital PCR, and advanced molecular panels deliver deeper genomic insights across hundreds of cancer‐related mutations.

• Labs are increasingly adopting liquid biopsies and MRD (Minimal Residual Disease) monitoring - non‐invasive approaches that can detect relapse earlier and with higher sensitivity.

• Tools infused with Artificial Intelligence (AI) and machine learning accelerate analysis while enhancing accuracy and reproducibility - cutting turnaround times and enabling more nuanced interpretation of complex genomic data.

• Clinicians increasingly require companion diagnostics - tests that inform which therapies patients are most likely to benefit from.

• Personalized profiling ensures that a patient's unique tumor biology guides treatment decisions, boosting both clinical outcomes and test utilization.

• Regulatory and payer ecosystems are aligning with these needs, enabling better reimbursement and broader clinical adoption of precision diagnostic tools.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=hemato-oncology-testing-market?pratik

Hemato Oncology Testing Market Major Players:-

F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., and Adaptive Biotechnologies.

Key players highlights:-

1) F. Hoffmann‐La Roche Ltd. - 12.8% market share, the largest individual player in hemato‐oncology testing globally due to broad diagnostics portfolio and global reach. Roche leads with extensive test offerings spanning leukemia, lymphoma, and targeted molecular profiles.

2) Abbott Laboratories - One of the leading diagnostic companies with strong share in hemato oncology testing driven by robust assay kits and integrated solutions. Abbott's broad clinical diagnostics footprint supports high adoption in routine and advanced cancer testing.

3) Thermo Fisher Scientific, Inc. - Holds a significant share (12% ) with its NGS systems and assay kits used globally in clinical labs. Thermo Fisher supports comprehensive molecular workflows for hemato oncology diagnostics.

4) Illumina, Inc. - Around 14% share in related hematologic oncology/genomic testing markets through high‐throughput sequencing platforms widely used in oncology profiling. Illumina's NGS technologies enable deep mutation profiling in hematologic cancer diagnostics.

5) Qiagen N.V. - A key player offering PCR/NGS‐based assay kits and sample prep solutions, contributing to its strong presence in hemato oncology diagnostics. Qiagen's products support sensitive detection and sub‐typing of blood cancers across laboratories worldwide.

Hemato Oncology Testing Market Regional Highlights

North America
• 41.32% share of the global hemato oncology testing market, making it the largest regional segment.
• Market growth driven by advanced healthcare infrastructure, high R&D spending, precision medicine adoption.
• Ongoing developments include new molecular and liquid biopsy test integration and strategic lab acquisitions.

Europe
• 28.56% of the global market, second‐largest region.
• Growth supported by established healthcare systems, government funding, and early cancer detection initiatives.
• Key developments include adoption of advanced diagnostics in Germany, UK, and France with supportive regulatory frameworks.

Asia‐Pacific
• 23.21% share, with fastest growth rates among major regions.
• Expansion driven by rising healthcare investment, wider access to testing, and growing blood cancer prevalence.
• Developments include increased adoption of NGS and liquid biopsy tools in China, India, and Japan.

Latin America
• 7 of the global market share.
• Growth propelled by modernization of diagnostic labs and increased access to advanced testing tools.
• Developments focus on expanding testing in Brazil and Mexico through healthcare investments.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/hemato-oncology-testing-market?pratik

Market Segmentation:-

The Hemato Oncology Testing Market is segmented by type of product, which includes instruments, reagents and consumables, and services, catering to diverse testing needs. Based on technology, the market covers PCR, immunohistochemistry (IHC), next-generation sequencing (NGS), cytogenetics, and other advanced diagnostic methods. In terms of cancer type, it serves patients with leukemia, acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, multiple myelomas, and other hematologic cancers. By end-user, the market targets clinical laboratories, hospitals, academic and research institutes, among others. Geographically, the market spans regions including North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa, reflecting global demand and adoption.

Hemato Oncology Testing Market - FAQs

Q: What is driving the growth of the Hemato Oncology Testing Market?
A: Rising prevalence of hematologic cancers, adoption of advanced diagnostics like NGS and PCR, and increasing demand for personalized therapies.

Q: Which technologies dominate the Hemato Oncology Testing Market?
A: PCR, NGS, IHC, and cytogenetics are the leading technologies used for accurate diagnosis and monitoring.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.